Article
Illumina defends $7.1 bln Grail buy to fend off antitrust regulators
Rating:
0.0
Views:
58
Likes:
1
Library:
1
U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its DNA sequencing services to other firms, as it seeks to head off a potential vote by U.S. antitrust regulators to kill the deal.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value